Health & Fitness

The Uromigos

by The Uromigos

Is this your show? Claim it

Listen on Apple Podcasts RSS feed

Recently ranked · United States

Last recorded placements from this show’s chart history. These are not current rankings.

Not on the United States charts we track today.

If you like The Uromigos, try…

ウロミーゴス

From The Uromigos

The NRG Oncology Podcast

Latest episodes

Episode 529: ESMO 2026 - LITESPARK-011 Updated Results including Overall Survival

October 25, 2026 · 31 min

Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!
Episode 528: ESMO 2026 - LITESPARK 012

October 25, 2026 · 44 min

Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!
Episode 527: ESMO 2026 - DASL-HiCaP Adding Darolutamide to ADT and XRT in High-risk Localized Prostate Cancer

October 24, 2026 · 38 min

Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.
Episode 526: ESMO 2026 - The VOLGA trial in MIBC

October 24, 2026 · 37 min

Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
Episode 525: ESMO 2026 - PEACE-1 and CAPItello-281

October 24, 2026 · 47 min

Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC

Show 7 more episodesShow fewer episodes

Episode 524: ESMO 2026 - JNJ-6143, a Novel RIPTAC in mCRPC

October 24, 2026 · 16 min

Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell transcription.
Episode 523: ESMO 2026: ctDNA Kinetics from Neoadjuvant EVP in MIBC

October 23, 2026 · 36 min

Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

October 23, 2026 · 24 min

Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.
Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

October 23, 2026 · 33 min

Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.
Episode 520: ESMO 2026 Preview

October 12, 2026 · 55 min

Silke, Brian and Tom preview the major data to be presented at ESMO 2026
Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

October 5, 2026 · 33 min

Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).
Episode 518: PSMAddition in Clinical Practice

September 28, 2026 · 31 min

Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk

Full episode archive on Apple Podcasts →

About the show

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London